466 related articles for article (PubMed ID: 35926270)
1. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
Hu L; Liu R; Zhang L
Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
[TBL] [Abstract][Full Text] [Related]
2. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
3. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
Shimizu T; Kawashiri SY; Morimoto S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Kiya R; Sato S; Yamamoto H; Kawakami A
Trials; 2023 Mar; 24(1):161. PubMed ID: 36869356
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
7. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
[TBL] [Abstract][Full Text] [Related]
8. Genkwanin ameliorates adjuvant-induced arthritis in rats through inhibiting JAK/STAT and NF-κB signaling pathways.
Bao Y; Sun YW; Ji J; Gan L; Zhang CF; Wang CZ; Yuan CS
Phytomedicine; 2019 Oct; 63():153036. PubMed ID: 31401534
[TBL] [Abstract][Full Text] [Related]
9. Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.
Boyce BF; Li J; Xing L; Yao Z
Front Immunol; 2018; 9():2263. PubMed ID: 30323820
[TBL] [Abstract][Full Text] [Related]
10. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.
Srivastava S; Rasool M
Life Sci; 2022 Jun; 298():120516. PubMed ID: 35367240
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors for rheumatoid arthritis.
Kubo S; Nakayamada S; Tanaka Y
Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
[TBL] [Abstract][Full Text] [Related]
12. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
13. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Romas E; Gillespie MT; Martin TJ
Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.
Wen H; Liu Y; Li J; Wei D; Liu D; Zhao F
Clin Exp Rheumatol; 2018; 36(5):798-805. PubMed ID: 29465363
[TBL] [Abstract][Full Text] [Related]
15. JAK1: Number one in the family; number one in inflammation?
Spinelli FR; Colbert RA; Gadina M
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
[TBL] [Abstract][Full Text] [Related]
16. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
17. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
18. Nicorandil and theophylline can protect experimental rats against complete Freund's adjuvant-induced rheumatoid arthritis through modulation of JAK/STAT/RANKL signaling pathway.
Gaafar AGA; Messiha BAS; Abdelkafy AML
Eur J Pharmacol; 2018 Mar; 822():177-185. PubMed ID: 29337196
[TBL] [Abstract][Full Text] [Related]
19. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
20. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]